Efficacy and safety of early pancreatic duct stenting for unresectable pancreatic cancer: A randomized controlled trial

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-2)

Tables (1-7)

Sum=106

Publishing Process of This Article

Item

Count

Browse

Download

Sum=5

Apr 15, 2025 (publication date) through Mar 28, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastrointest Oncol. Apr 15, 2025; 17(4): 103311
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103311

Table 1 Early pancreatic duct stenting for unresectable pancreatic cancer

	The inclusion and exclusion criteria
Inclusion criteria	(1) Diagnosed with pancreatic cancer
	(2) Confirmed unresectable pancreatic cancer (according to 8^th edition of the AJCC cancer staging manual)
	(3) Age ≥ 18 years old
	(4) Presence of biliary obstruction: Imaging showed that the bile duct diameter was greater than 1.0 cm with elevated direct bilirubin (greater than 50 mmol/L)
	(5) The diameter of the main pancreatic duct is less than 5 mm
	(6) Pain score ≤ 4 point
Exclusion criteria	(1) Unable to give informed consent
	(2) Life expectancy of less than 4 weeks
	(3) Pregnancy
	(4) Severe comorbidities precluding the endoscopic procedure (such as cardiopulmonary disease, sepsis, or a bleeding disorder)

AJCC: The American Joint Committee on Cancer.

Citation: Sun MH, Shen HZ, Jin HB, Yang JF, Zhang XF. Efficacy and safety of early pancreatic duct stenting for unresectable pancreatic cancer: A randomized controlled trial. World J Gastrointest Oncol 2025; 17(4): 103311
URL: https://www.wjgnet.com/1948-5204/full/v17/i4/103311.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i4.103311